Merck & Co., Inc. (MRK) to Issue Quarterly Dividend of $0.85 on October 7th

Merck & Co., Inc. (NYSE:MRK) declared a quarterly dividend on Wednesday, July 29th. Investors of record on Tuesday, September 15th will be given a dividend of 0.85 per share on Wednesday, October 7th. This represents a c) annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th.

Merck & Co., Inc. has increased its dividend payment by an average of 0.1%per year over the last three years and has raised its dividend every year for the last 14 years. Merck & Co., Inc. has a dividend payout ratio of 35.0% indicating that its dividend is sufficiently covered by earnings. Analysts expect Merck & Co., Inc. to earn $9.66 per share next year, which means the company should continue to be able to cover its $3.40 annual dividend with an expected future payout ratio of 35.2%.

Merck & Co., Inc. Stock Down 0.5%

Shares of MRK opened at $144.02 on Friday. The stock has a market cap of $355.33 billion, a price-to-earnings ratio of 115.22, a P/E/G ratio of 6.26 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $156.92. The company has a 50-day moving average price of $136.51 and a two-hundred day moving average price of $124.40.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the previous year, the business earned $2.13 earnings per share. The company’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.